Zosano Pharma Corp Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2016-11-22: Form 8-K; Period of report 2016-11-22; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2016-11-09: Form 8-K; Period of report 2016-11-09; Description 2.02 Results of Operations and Financial Condition.
- 2016-11-03: Form 8-K; Period of report 2016-11-02; Description 5.07 Submission of Matters to a Vote of Security Holders; Details 5.07.
- 2016-10-14: Form 8-K; Period of report 2016-10-12; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 3.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2016-11-22 | 8-K | 2016-11-22 | 7.01 Regulation FD Disclosure | 7.01 On November 22, 2016, Zosano Pharma Corporation issued a press release announcing the sale of a nonstrategic asset. | d293492d8k.htm |
| 2016-11-09 | 8-K | 2016-11-09 | 2.02 Results of Operations and Financial Condition | d278799d8k.htm | |
| 2016-11-03 | 8-K | 2016-11-02 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On November 2, 2016, we held our annual meeting of stockholders. | d282758d8k.htm |
| 2016-10-14 | 8-K | 2016-10-12 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On October 12, 2016, Zosano Pharma Corporation (the “Company”) received written notice from The NASDAQ Stock Market, LLC (“NASDAQ”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market, as set forth in Listing Rule 5550(a)(2). | d28835d8k.htm |
| 2016-09-09 | 8-K | 2016-09-07 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 7, 2016, our Board of Directors appointed Georgia Erbez as the Company’s Chief Business Officer. | d256657d8k.htm |
| 2016-08-16 | 8-K | 2016-08-15 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 3.02 The disclosures set forth in Item 1.01 above are incorporated herein for this Item 3.02. 8.01 On August 16, 2016, the Company issued a press release titled “Zosano Pharma Announces Pricing of Private Placement of Common Stock and Warrants.” A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. | d229014d8k.htm |
| 2016-08-10 | 8-K | 2016-08-10 | 2.02 Results of Operations and Financial Condition | d223248d8k.htm | |
| 2016-06-17 | 8-K | 2016-06-15 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 15, 2016, the board of directors of Zosano Pharma Corporation (the “Company”) appointed Georgia Erbez as Interim Chief Financial Officer of the Company. | d213636d8k.htm |
| 2016-05-13 | 8-K | 2016-05-13 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On May 13, 2016, Zosano Pharma Corporation (the “Company”) announced that Winnie Tso, Chief Financial Officer, will be on a temporary medical leave of absence, effective immediately. | d154345d8k.htm |
| 2016-05-12 | 8-K | 2016-05-12 | 2.02 Results of Operations and Financial Condition | d192929d8k.htm | |
| 2016-05-09 | 8-K | 2016-05-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On May 4, 2016, our Board of Directors appointed John Walker as a Class I director and the Chairman of the Board of Directors. | d177250d8k.htm |
| 2016-04-07 | 8-K | 2016-04-07 | 7.01 Regulation FD Disclosure | 7.01 A copy of the Company’s current investor presentation is attached to this Current Report on Form 8-K as Exhibit 99.1. | d155439d8k.htm |
| 2016-03-29 | 8-K | 2016-03-24 | 2.02 Results of Operations and Financial Condition; 2.05 Costs Associated with Exit or Disposal Activities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 2.05 On March 24, 2016, we implemented a restructuring initiative which includes a workforce reduction of 24 employees, representing approximately 38% of our current total workforce in order to reduce operating expenses and conserve cash resources. 5.02 The employment of Laxmi Peri, our Senior Vice President, Operations, was terminated on March 24, 2016 as part of the reduction-in-force described above. | d141098d8k.htm |
| 2016-02-04 | 8-K | 2016-02-03 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 3, 2016, our Board of Directors appointed Konstantinos Alataris, Ph.D., our Chief Executive Officer and President, as a Class I director to fill a vacancy on the Board. | d133389d8k.htm |
| 2016-01-27 | 8-K | 2016-01-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Under the rules of The NASDAQ Stock Market, independent directors must comprise a majority of a listed company’s board of directors within 12 months from the date of listing in connection with the company’s initial public offering. | d14740d8k.htm |
| 2016-01-07 | 8-K | 2016-01-06 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On January 6, 2016, the employment of Vikram Lamba as our Chief Executive Officer was terminated without cause by our Board of Directors. 8.01 On January 7, 2016, we issued a press release entitled “Zosano Pharma Announces Appointment of Konstantinos Alataris, Ph.D. as President and Chief Executive Officer,” which is attached hereto as Exhibit 99.1. | d118328d8k.htm |